Elosulfase Alfa: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Elosulfase Alfa. Educational only — not medical advice.

Labeled uses

VIMIZIM (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).

Source: FDA labeling via NIH DailyMed (set 0caa2565…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.